Tackling the most impactful AI challenge of our time:
Predicting which drug candidates actually work.
Quris is an artificial intelligence innovator that is disrupting the drug development process.
Quris' Bio-AI Clinical Prediction Platform better predicts which drug candidates will safely work in humans, avoiding tremendous costs of failed clinical trials.
We are led by a team of top scientists and strategic investors and are actively preparing for clinical testing with our first AI-based drug.
First AI Clinical Prediction Platform
Drug development is expensive, with 89% of drugs ultimately failing in clinical trials. Quris aims to address the trillion-dollar challenge that other unicorn AI-Pharma companies have not: Predicting which drug candidate will safely work in humans. More…
Machine-Learning Trained by Patients-on-a-Chip
Our unique machine-learning approach generates data for classification algorithms by testing drugs on miniaturized Patients-on-a-Chip and then the machine-learning model is trained using this automatically-tagged data. More…
First AI Drug Heading Towards Clinical Trials
The first proprietary drug developed using our Bio-AI Clinical Prediction Platform is preparing to enter a Phase 1 clinical trial in 2022. It is a drug for Fragile-X Syndrome, a cause of autism and cognitive disability. Where other large pharma has failed, our drug now brings new hope. More…
An All-Star Team
Based in Boston and Tel-Aviv, Quris is led by a stellar team of pioneers in machine-learning, big-data, genomics, technology, and medical device development - all with a strong track record of success, including Moderna co-founder Robert Langer and Nobel Laureate Aaron Ciechanover. More…